Our core content on Lung conditions and related factsheets has been translated to a number of other languages.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
European Lung Foundation
Our core content on Lung conditions and related factsheets has been translated to a number of other languages by our volunteer team.
For more languages explore all available Factsheet translations.
Volunteer as a translator or learn how to translate using Chrome, Firefox or Edge browsers.
Researchers in Singapore have found that a drug used to treat diabetes could also increase the effectiveness of tuberculosis (TB) medication.
Details of the study have been published in the journal, Science Translational Medicine.
Typically, TB-fighting drugs are designed to attack and kill the bacteria that cause the disease directly. However, this approach has given rise to an increase in strains of the disease that are resistant to antibiotics. The researchers proposed that a new, indirect method of fighting TB could form a better strategy that does not encourage drug resistance.
After looking through a range of drugs for a potential new treatment, the scientists found that metformin, a drug used to treat diabetes, was effective, particularly when combined with traditional TB medicines.
The drug now needs to be tested in clinical trials, however, as the researchers highlight, since metformin is currently in use, these should not be too lengthy.
Sign up to our free monthly newsletter to get the latest information and research news on lung conditions, plus views from experts and patients! You can unsubscribe at any time.
ELF is a non-profit organisation registered as a UK company (VAT no. GB 115 0027 74) and charity (no. 1118930).
Our Brussels office enterprise number is 0738.383.695
European Lung Foundation's TR ID number in the Transparency Register is: 094039644810-79